Cencora, Inc. vs McKesson Corporation: Strategic Comparison

This in-depth comparison examines Cencora, Inc. and McKesson Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cencora, Inc. on its own, evaluating McKesson Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cencora, Inc. and McKesson Corporation is widest.

On the headline numbers, Cencora, Inc. reports annual revenue of $321.3B against $403.4B for McKesson Corporation, while their respective market capitalizations stand at $59.0B and N/A. Cencora, Inc. is headquartered in United States and McKesson Corporation operates from United States, and those different home markets shape how each company competes.

Cencora, Inc.: Cencora sits between drug makers such as Pfizer, Merck and Eli Lilly and the pharmacies, hospitals and clinics that dispense medicine. Along with McKesson and Cardinal Health it handles the large majority of U.S. prescription drug distribution. It reports two segments, U.S. Healthcare Solutions (about $74.9 billion of revenue in the June 2026 quarter) and International Healthcare Solutions (about $7.7 billion), plus other businesses including MWI Animal Health. The company does not make drugs; its value lies in logistics, compliance, purchasing and services for manufacturers and providers.

McKesson Corporation: McKesson is best understood as healthcare infrastructure. It moves medicines through a regulated network and supports providers and manufacturers with specialty distribution, oncology services, patient-access programs, technology, and medical supplies. The strategic shift is toward higher-growth oncology, multispecialty, and biopharma services while simplifying the portfolio through the European exit and planned Medical-Surgical separation.

Cencora, Inc. and McKesson Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cencora, Inc. and McKesson Corporation.

Cencora, Inc. business model: Cencora makes money on volume and services rather than markups alone. It buys medicines from manufacturers, holds them in a national network of distribution centers and delivers them, often overnight, to pharmacies, hospitals, clinics and physician offices. Revenue is enormous because the full drug price passes through its books, but adjusted gross margin is only around 4% (4.16% in the June 2026 quarter). Profit comes from distribution service fees paid by manufacturers, generic-drug sourcing, specialty distribution of oncology and other biologics, and services such as World Courier clinical-trial logistics, commercialization and market-access consulting, and management services organizations (MSOs) for retina and oncology practices.

McKesson Corporation business model: McKesson makes money primarily by purchasing and distributing pharmaceuticals and medical products to pharmacies, hospitals, health systems, and other providers. Distribution is a high-volume, thin-margin business, so purchasing terms, logistics efficiency, order accuracy, customer contracts, and working-capital management drive results. The company also earns service revenue through oncology and multispecialty provider platforms, biopharma services, prescription access and affordability tools, third-party logistics, and medical-surgical distribution.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cencora, Inc. stack up against those of McKesson Corporation.

Cencora, Inc. competitive advantage: Cencora's advantage is scale that is hard to copy: a national distribution network built for temperature-sensitive and controlled products, purchasing power with manufacturers, and deep specialty relationships. It is the leading distributor to community oncology practices and, through Retina Consultants of America and OneOncology, now also manages physician networks that prescribe high-cost specialty drugs. A long-term distribution contract with Walgreens through 2029 provides a large base of recurring volume.

McKesson Corporation competitive advantage: McKesson's advantage is the combination of distribution scale, regulated logistics, supplier and customer relationships, specialty capabilities, and nationwide infrastructure. Those assets are expensive and difficult to replicate, but large customers retain negotiating power and the core distribution model remains sensitive to small changes in pricing, product mix, and costs.

Future prospects matter as much as current results. The growth strategies below explain how Cencora, Inc. and McKesson Corporation each plan to expand from here.

Cencora, Inc. growth strategy: Cencora calls its strategy pharmaceutical-centric. Since 2024 it has redeployed capital toward specialty care: it bought about 85% of Retina Consultants of America for roughly $4.6 billion (closed January 2025) and agreed in December 2025 to buy the majority of OneOncology it did not already own from TPG and others for about $3.6 billion (closed February 2026). In February 2026 it agreed to merge MWI Animal Health into Covetrus, keeping a minority stake, which narrows its focus on human pharmaceuticals. International growth comes through Alliance Healthcare in Europe, Innomar in Canada and World Courier specialty logistics.

McKesson Corporation growth strategy: McKesson is concentrating capital on oncology, multispecialty care, and biopharma services, where provider relationships and specialty capabilities can grow faster than traditional wholesale distribution. It is also expanding prescription access and affordability services, completing its exit from Europe, and pursuing a separation of Medical-Surgical Solutions. The objective is a more focused portfolio with better profit growth while preserving the reliability and cash generation of North American pharmaceutical distribution.

A closer look at the financial trajectory of Cencora, Inc. and McKesson Corporation rounds out the comparison.

Cencora, Inc.: Cencora's revenue rose from $238.6 billion in FY2022 to $321.3 billion in FY2025, while FY2025 net income attributable to Cencora was about $1.55 billion, a net margin of roughly half a percent. Growth in fiscal 2026 has been driven by specialty products, GLP-1 volume and the newly consolidated OneOncology. In the third quarter ended June 30, 2026, revenue grew 5.1% to $84.8 billion, adjusted operating income rose 17% to $1.2 billion, adjusted diluted EPS rose 12% to $4.48, and the company repurchased $1 billion of stock. Management raised fiscal 2026 adjusted EPS guidance to $17.75-$17.95 and expects about $3 billion of adjusted free cash flow.

McKesson Corporation: McKesson reported fiscal 2026 revenue of $403.4 billion, up 12%, operating cash flow of $6.2 billion, and free cash flow of $5.4 billion. North American Pharmaceutical produced $336.7 billion of revenue; Oncology & Multispecialty produced $48.4 billion; Prescription Technology Solutions produced $5.8 billion; and Medical-Surgical Solutions produced $11.5 billion. Revenue should be read alongside segment profit and cash flow because distribution and retail represented about 98% of consolidated revenue but operate on thin margins.